A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
NCT ID: NCT00652925
Last Updated: 2008-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
225 participants
INTERVENTIONAL
2002-10-31
2005-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High Dose
Celecoxib
Higher dose, 6 mg/kg/dose BID
Low Dose
Celecoxib
Active drug at lower dose
Naproxen
Control comparator, 15 mg/kg/dy target dose
Naproxen
Control comparator, 15 mg/kg/dy target dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Celecoxib
Higher dose, 6 mg/kg/dose BID
Celecoxib
Active drug at lower dose
Naproxen
Control comparator, 15 mg/kg/dy target dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Hartford, Connecticut, United States
Pfizer Investigational Site
Delray Beach, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
St. Petersburg, Florida, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Glenview, Illinois, United States
Pfizer Investigational Site
Hinsdale, Illinois, United States
Pfizer Investigational Site
Merrillville, Indiana, United States
Pfizer Investigational Site
New Orleans, Louisiana, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Worcester, Massachusetts, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Livingston, New Jersey, United States
Pfizer Investigational Site
New Hyde Park, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Tulsa, Oklahoma, United States
Pfizer Investigational Site
Tulsa, Oklahoma, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Altoona, Pennsylvania, United States
Pfizer Investigational Site
Altoona, Pennsylvania, United States
Pfizer Investigational Site
Duncansville, Pennsylvania, United States
Pfizer Investigational Site
Hershey, Pennsylvania, United States
Pfizer Investigational Site
Johnstown, Pennsylvania, United States
Pfizer Investigational Site
Lancaster, Pennsylvania, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Pfizer Investigational Site
Århus N, , Denmark
Pfizer Investigational Site
Vandœuvre-lès-Nancy, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Bremen, , Germany
Pfizer Investigational Site
Halle, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Hanover, , Germany
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Pfizer Investigational Site
Guadalajara, , Mexico
Pfizer Investigational Site
Lima, Lima Province, Peru
Pfizer Investigational Site
Lima, Lima Province, Peru
Pfizer Investigational Site
Lima, Lima Province, Peru
Pfizer Investigational Site
Vila Nova de Famalicão, , Portugal
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Piešťany, , Slovakia
Pfizer Investigational Site
Ljubljana, , Slovenia
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3191127
Identifier Type: -
Identifier Source: secondary_id
N49-01-02-195
Identifier Type: -
Identifier Source: org_study_id